- Home
- AUPH vs COLL Comparison
AUPH vs COLL Comparison
Compare AUPH & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- COLL
- Stock Information
- Founded
- AUPH 1993
- COLL 2002
- Country
- AUPH Canada
- COLL United States
- Employees
- AUPH N/A
- COLL N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- AUPH Health Care
- COLL Health Care
- Exchange
- AUPH Nasdaq
- COLL Nasdaq
- Market Cap
- AUPH 1.3B
- COLL 1.1B
- IPO Year
- AUPH 1999
- COLL 2015
- Fundamental
- Price
- AUPH $9.50
- COLL $30.92
- Analyst Decision
- AUPH Strong Buy
- COLL Strong Buy
- Analyst Count
- AUPH 3
- COLL 6
- Target Price
- AUPH $10.33
- COLL $42.00
- AVG Volume (30 Days)
- AUPH 1.5M
- COLL 439.3K
- Earning Date
- AUPH 11-07-2024
- COLL 11-07-2024
- Dividend Yield
- AUPH N/A
- COLL N/A
- EPS Growth
- AUPH N/A
- COLL 757.11
- EPS
- AUPH N/A
- COLL 2.16
- Revenue
- AUPH $220,361,000.00
- COLL $599,245,000.00
- Revenue This Year
- AUPH $36.97
- COLL $13.20
- Revenue Next Year
- AUPH $16.43
- COLL $17.63
- P/E Ratio
- AUPH N/A
- COLL $14.32
- Revenue Growth
- AUPH 38.72
- COLL 9.62
- 52 Week Low
- AUPH $4.71
- COLL $28.97
- 52 Week High
- AUPH $10.67
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- AUPH 58.10
- COLL 48.70
- Support Level
- AUPH $9.22
- COLL $29.67
- Resistance Level
- AUPH $9.76
- COLL $31.10
- Average True Range (ATR)
- AUPH 0.42
- COLL 0.98
- MACD
- AUPH -0.02
- COLL 0.26
- Stochastic Oscillator
- AUPH 36.73
- COLL 69.41
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.